{"id":"doi:10.1007/s00213-020-05719-1","kind":"review","title":"Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants","authors":["Nicole Leite Galvão Coelho","Wolfgang Marx","Maria Gonzalez","Justin Sinclair","Michael de Manincor","Daniel Perkins","Jerome J. Sarris"],"author_count":7,"year":2021,"published":"2021-01-11","venue":"Psychopharmacology","cited_by":137,"doi":"10.1007/s00213-020-05719-1","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1007/s00213-020-05719-1","archive_url":"https://space-kitty.com/papers/doi:10.1007/s00213-020-05719-1","updated":null,"pmid":"33427944","pmcid":"PMC7826317","openalex_id":"W3120778817","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00213-020-05719-1.pdf","abstract":"RATIONALE: Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic treatment option. OBJECTIVE: We present the first meta-analytic review evaluating the clinical effects of classic serotonergic psychedelics vs placebo for mood state and symptoms of depression in both healthy and clinical populations (separately). RESULTS: Our search revealed 12 eligible studies (n = 257; 124 healthy participants, and 133 patients with mood disorders), with data from randomized controlled trials involving psilocybin (n = 8), lysergic acid diethylamide ([LSD]; n = 3), and ayahuasca (n = 1). The meta-analyses of acute mood outcomes (3 h to 1 day after treatment) for healthy volunteers and patients revealed improvements with moderate significant effect sizes in favor of psychedelics, as well as for the longer-term (16 to 60 days after treatments) mood state of patients. For patients with mood disorder, significant effect sizes were detected on the acute, medium (2-7 days after treatment), and longer-term outcomes favoring psychedelics on the reduction of depressive symptoms. CONCLUSION: Despite the concerns over unblinding and expectancy, the strength of the effect sizes, fast onset, and enduring therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing them for management of negative mood and depressive symptoms.","abstract_license":"CC-BY (publisher license, via OpenAlex)","license":"cc-by","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Psychedelics and Drug Studies"],"details":null,"provenance":"openalex+europepmc","attribution":"Abstract of \"Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants\" by Nicole Leite Galvão Coelho, Wolfgang Marx, Maria Gonzalez et al., https://doi.org/10.1007/s00213-020-05719-1, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[]}